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ABSTRACT
Sustained parathyroid hormone (PTH) elevation stimulates bone remodeling (ie, both resorption and formation). The former results from
increased RANKL synthesis, but the cause of the latter has not been established. Current hypotheses include release of osteoblastogenic
factorsfromosteoclastsorfromthebonematrixduringresorption,modulationoftheproductionandactivityofosteoblastogenicfactors
from cells of the osteoblast lineage, and increased angiogenesis. To dissect the contribution of these mechanisms, 6-month-old Swiss-
Webster mice were infused for 5 days with 470ng/h PTH(1-84) or 525ng/h soluble RANKL (sRANKL). Both agents increased osteoclasts
andosteoblastsinvertebralcancellousbone,buttheratioofosteoblasts toosteoclastsandtheincreaseinboneformationwasgreaterin
PTH-treated mice. Cancellous bone mass was maintained in mice receiving PTH but lost in mice receiving sRANKL, indicating that
maintenance of balanced remodeling requires osteoblastogenic effects beyond those mediated by osteoclasts. Consistent with this
contention, PTH, but not sRANKL, decreased the level of the Wnt antagonist sclerostin and increased the expression of the Wnt target
genes Nkd2, Wisp1, and Twist1. Furthermore, PTH, but not sRANKL, increased the number of blood vessels in the bone marrow. Weekly
injections of the RANKL antagonist osteoprotegerin at 10mg/g for 2 weeks prior to PTH infusion eliminated osteoclasts and osteoblasts
and prevented the PTH-induced increase in osteoclasts, osteoblasts, and blood vessels. These results indicate that PTH stimulates
osteoclast-dependent as well as osteoclast-independent (Wnt signaling) pro-osteoblastogenic pathways, both of which are required for
balanced focal bone remodeling in cancellous bone.  2010 American Society for Bone and Mineral Research.
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Introduction
D
uring bone remodeling, old bone is removed and replaced
with new by teams of osteoclasts and osteoblasts,
collectively called the basic multicellular unit (BMU). In cancellous
bone, the BMU is separated from the marrow by a canopy of flat
cells in close association with blood vessels lying just outside the
canopy.
(1,2) Hypoparathroidism and hyperparathyroidism lead to
a decrease or increase in the number of BMUs, respectively,
consistent with a major role of parathyroid hormone (PTH) in the
rate of bone remodeling.
(3,4) A remarkable feature of PTH-
regulated remodeling in cancellous bone is that the number of
osteoblasts recruited to the BMU is sufficient to completely refill
the resorption cavity. Indeed, cancellous bone is maintained or
increases in hyperparathyroidism,
(5) while cortical bone is lost in
this condition.
PTH initiates new BMUs by promoting the differentiation of
osteoclasts from circulating hematopoietic progenitors. This
effect is mediated by a stimulatory effect of the hormone on the
synthesis of receptor activator of NF-kB ligand (RANKL)
(6,7)—a
membrane-bound cytokine that binds to RANK on osteoclast
progenitors and stimulates their differentiation. The pro-
osteoclastogenic effect of PTH is intensified by its ability to
suppress the production of osteoprotegerin (OPG), a soluble
decoy receptor for RANKL. The importance of PTH-stimulated
RANKL synthesis for the control of the rate of bone remodeling is
highlighted by evidence that deletion of a PTH-responsive
enhancer of RANKL gene transcription attenuates expression of
this cytokine and reduces the rate of bone remodeling in adult
mice.
(8)
Several mechanisms have been proposed to explain the
coupling of bone formation to bone resorption within the BMU.
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2427Oneofthe mechanismsisthereleaseoffactors from thecalcified
bone matrix during bone resorption, such as insulin-like growth
factors (IGFs), bone morphogenetic proteins (BMPs), and
transforming growth factor b (TGF-b),
(9–11) that stimulate
osteoblast differentiation. Osteoclasts themselves also produce
several pro-osteogenic agents, including cardiotropin 1,
(12)
sphingosine-1-phosphate, and BMP-6.
(13) The existence of an
osteoclast-mediated pro-osteoblastogenic mechanism is sup-
ported by evidence that administration of soluble RANKL
(sRANKL) to rats or mice increases serum markers of both bone
formation and bone resorption.
(14,15) PTH also acts on cells of the
osteoblast lineage, including osteocytes, to affect the expression
and activity of a variety of pro-osteoblastogenic growth
factors.
(16–18) PTH stimulation of canonical Wnt signaling, which
is essential for osteoblast differentiation,
(19) may play a
particularly prominent role. Activation of the PTH receptor in
osteoblastic cells directly induces canonical Wnt signaling,
(20)
andsuppression ofthesynthesis oftheWntantagonistsclerostin
by osteocytes may intensify this pro-osteoblastogenic signal
further.
(21,22) The powerful role of sclerostin-mediated inhibition
of bone formation is highlighted by the dramatic increase in
bone formation in ovariectomized rats following administration
of an antisclerostin antibody.
(23,24)
PTH also may regulate osteoblast differentiation via effects on
angiogenesis because bone formation during development,
fracture healing,
(25) and remodeling
(1,2) almost always takes
place in close proximity to capillaries. The linkage of angiogen-
esis and osteoblastogenesis may be due in part to the fact that
mesenchymal stem cell progenitors of osteoblasts are located
on the outside surfaces of blood vessels.
(26) Furthermore, PTH
stimulates the production of angiopoetin 1 by osteoblastic
cells
(27) and of vascular endothelial growth factor (VEGF) by
endothelial cells;
(28) and vascular endothelial cells produce a
variety of pro-osteoblastogenic factors.
(25)
Here we examined the potential contribution of these three
pathways to the increase in osteoblasts caused by continuous
elevationofPTH.WeshowinmicethatinfusionofPTH stimulates
balanced focal remodeling of cancellous bone, whereas infusion
of sRANKL causes unbalanced remodeling and bone loss. Hence
the osteoclast-dependent pro-osteoblastogenic mechanism, in
and of itself, does not generate a sufficient number and quality of
osteoblasts to refill the resorption cavity. We also show that PTH,
but not sRANKL, stimulates Wnt signaling as well as angiogenesis.
Interestingly, pretreatment of mice with OPG-Fc blocks both the
pro-osteoblastogenic and the proangiogenic effects of the
hormone. Weconclude that PTH stimulates osteoclast-dependent
and -independent (Wnt signaling) pro-osteoblastogenic path-
ways, both of which are required for balanced focal bone
remodeling in cancellous bone.
Materials and Methods
Animals
Female Swiss-Webster mice (6 months old, 29 to 31g) were
obtained from Harlan (Indianapolis, IN, USA) and were main-
tained and used in accordance with NIH guidelines. Animal use
protocols were approved by the Institutional Animal Care and
Use Committees of the University of Arkansas for Medical
Sciences and the Central Arkansas Veterans Healthcare System.
Mice were fed a standard rodent diet (Teklad 22/5, Harlan)
containing 22% protein, 1.13% calcium, and 0.94% phosphorus.
Mice were injected every 7 days with PBS (vehicle) or 10mg/g of
humanOPG-Fc(providedbyPaulKostenuik,Amgen,Seattle,WA,
USA). After 14 days of this pretreatment, mice were infused for
5 days with 0.001% b-mercaptoethanol, 0.06% acetic acid (PTH
vehicle), 470ng/h PTH(1-84) (Bachem, Torrance, CA, USA), or
525ng/h recombinant human sRANKL (provided by Paul
Kostenuik, Amgen) dissolved in PBS using microosmotic pumps
delivering fluid at 1 mL/h (Durect Corp., Cupertino, CA, USA).
Pumps were implanted into an interscapular subcutaneous
pocketunderanesthesia,asdescribedpreviously.
(29)Tetracycline
(30mg/kg, i.p.) was given 2 days prior to beginning the infusion,
and alizarin red (30mg/kg, i.p.) was given 2 days before the end
of the experiment to permit determination of the bone-
formation rate. Serum was obtained by retroorbital bleeding
for measurement of osteocalcin (Biomedical Technologies,
Soughton, MA) at the end of the experiment.
Micro–computed tomography (mCT)
mCT analysis of femurs and lumbar vertebrae (L4) was done after
the bones were dissected, cleaned, fixed in 10% Millonig’s
formalin, and transferred to ethanol. Bones were imaged by mCT
(mCT40, Scanco Medical, Basserdorf, Switzerland). Scans were
integrated into 3D voxel images (1024 1024 pixel matrices for
each individual planar stack). A Gaussian filter (s¼0.8,
support¼1) was used to reduce signal noise, and a threshold
of 200 was applied to all analyzed scans. Scans were done at
12-mm resolution (E¼55 kVp, I¼145mA, integration time¼
200ms). All trabecular measurements were made by manually
drawing contours every 10 to 20 slices and using voxel counting
for determination of bone volume per tissue volume. Calculation
of trabecular microarchitecture was done using sphere-filling
distance-transformation indices without assumptions about the
bone shape as a rod or plate.
Histomorphometry
After fixation in Millonig’s formalin, lumbar vertebrae (L1–L3)
were embedded nondecalcified in methyl methacrylate by
an automated procedure using a Tissue-Tek-VIP machine (Sakura
Finetek, Torrance, CA, USA). Histomorphometric analysis of bone
sections and detection of apoptotic osteoblasts by in situ nick-
end labeling (ISEL) were performed as described previously.
(30)
Measurements of cancellous bone were made in the entire
secondary spongiosa of all three vertebrae. Osteoblasts were
recognized by their juxtaposition to osteoid and counted only if
seen in groups of two or more. Osteoclasts were identified by
TRACPase staining. The bone-formation rate was calculated by
multiplying the mineral apposition rate by the linear extent of
the double-labeled perimeter. Because the tetracycline was
given prior to initiating the infusion protocol, changes in double-
labeled surfaces reflect actions of PTH and sRANKL on existing
BMUs.Thealizarinred–labeledperimeterwasusedasanindexof
osteoblast activity during the infusion period. Variables were
measured and reported as described previously
(30) using
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clature Committee of the ASBMR.
(31)
Blood vessels in the marrow space adjacent to the secondary
spongiosa were recognized by their content of red blood cells
and presence of CD34
þ endothelial cells. For the latter,
nondecalcified bone sections were deplasticized with 2-
methoxyethyl acetate and then sequentially rehydrated in
95%, 80%, and 70% ethanol and then water. After rinsing in PBS,
antigen retrieval was performed in a programmable histology
microwaveovenheatedto488Cfor1minutein0.01MNa-citrate,
pH 6, followed by incubation in 0.05% pepsin in 0.1N HCl for
30minutes at 378C. After rinsing, sections were quenched with
3% H2O2 in methanol and blocked with diluted normal mouse
serum. Sections were incubated overnight at 48C with a 1:50
dilution of mouse monoclonal anti-CD34 antibody (Vector
Laboratories, Inc., Burlingame, CA, USA). After rinsing, bound
antibody was visualized with a peroxidase-labeled secondary
antibody (Vector Laboratories, Inc.) according to the manufac-
turer’s instructions.
Western blotting
Sclerostin in lysates prepared from tibias was quantified by
Western blotting as described previously,
(21)except that 20mgo f
protein per lane was applied. Antisclerostin was from R&D
Systems (Minneapolis, MN, USA), anti–mouse b-actin was from
Sigma (St. Louis, MO, USA). Goat anti–mouse horseradish
peroxidase was from Santa Cruz Biotechnology (Santa Cruz,
CA, USA). Peroxidase labeling was detected using SuperSignal
West Pico Chemiluminescent Substrate (Pierce, Rockford, IL,
USA).Chemiluminescence wasquantifiedwithaVersaDocImage
System (Model 3000) and QuantityOne software (Biorad,
Hercules, CA, USA).
Transient transfection and luciferase assay
pcDNA was purchased from Invitrogen (Carlsbad, CA, USA). A
reporter plasmid carrying three Tcf binding sites upstream of a
minimal c-fos promoter driving the firefly Luciferase gene
(TOPFLASH)
(32) was provided by B Vogelstein (Johns Hopkins
University Medical Institutions, Baltimore, MD, USA). Osteoblastic
UAMS-32P cells
(33) or UMR 106 cells were transfected with the
reporter plasmid using Lipofectamine Plus (Invitrogen). Lucifer-
ase activity was determined 24hours later using the Dual-
Luciferase Reporter assay system (Promega, Madison, WI, USA).
Light intensity was measured with a luminometer, and the
Luciferase activity was divided by the Renilla activity (control
reporter) to normalize for transfection efficiency.
Quantitative PCR
RNA was extracted from lumbar vertebrae (L5) as described
previously.
(21) Transcripts were quantified by TaqMan PCR using
Assay-on-Demand primer and probe sets from Applied Biosys-
tems (Foster City, CA, USA).
Statistics
Data were analyzed by Student’s two-tailed t test or by ANOVA
using SigmaPlot and SigmaStat (SPSS Science, Chicago, IL, USA).
Values are reported as the mean SD. If necessary, data were
log-transformed to achieve a normal distribution. For ANOVA, p
values were Bonferroni-adjusted for the relevant number of post
hoc comparisons to control the overall error rate.
Results
Bone remodeling in female Swiss-Webster mice (6 months old)
wasstimulatedbyinfusingPTH(1-84)at470ng/hfor5daysusing
an osmotic pump. We have shown previously that this dose of
PTH and duration of infusion increase osteoclast and osteoblast
number,
(30) but peritrabecular fibroblasts, which are thought to
be arrested preosteoblasts,
(34) have not yet appeared. The
magnitude of the increase in osteoblast number thus reflects
PTH-regulated events that govern recruitment of osteoblasts to
the BMU in the absence of confounding effects of chronic
hyperparathyroidism. To determine the specific contribution of
osteoclast-dependent mechanisms of PTH-stimulated bone
formation, mice were infused for 5 days with recombinant
human sRANKL at 525ng/h. This dose was shown previously to
increase serum levels of TRACPase and osteocalcin after 3 or
7 days of administration in rats.
(14)
The experimental design is schematically depicted in Fig. 1A.
To investigate whether PTH can stimulate osteoblast differentia-
tion solely via osteoclast-independent mechanisms, bone was
depleted of osteoclasts by injecting mice with 10mg/g of
OPG-Fc,along-lastingformofOPG,
(14,15)at14and7dayspriorto
infusion of PTH. The OPG-Fc pretreatment protocol is based on
results from a preliminary experiment showing that a single
injection of OPG-Fc caused a rapid decline in osteoclasts
followed by a slower decline in osteoblasts, as reflected by
expression of cathepsin K and osteocalcin mRNA, respectively
(Fig. 1B). The slower decline in osteoblasts reflects their 10- to
14-day lifespan,
(35) during which time they elaborate a
collagenous matrix and then die by apoptosis or become
osteocytes or lining cells. Two weeks of OPG-Fc administration
achieved continued suppression of osteoclastogenesis and
complete depletion of osteoblasts prior to infusion of PTH (data
not shown).
Body weight was not affected by any of the treatments
(Table 1). PTH, but not sRANKL, increased total serum Ca,
consistent with a previous report.
(14) The PTH-stimulated
increase in serum calcium was abrogated by pretreatment with
OPG-Fc, reflecting the blockade of RANKL and thereby the
increased bone resorption caused by PTH (Table 1).
sRANKL, but not PTH, causes loss of vertebral cancellous
bone
mCT measurements indicated that PTH had no effect on the
cancellous architecture of lumbar vertebrae (L4) (Fig. 2). In
contrast, sRANKL caused a 25% reduction in cancellous bone
volume and in bone mineral density (BMD). The decreased bone
volume was due to reduced trabecular thickness, consistent with
unbalanced focal remodeling. Trabecular separation and
trabecularnumberwereunaffectedbysRANKL.Thusosteoclastic
perforation of individual trabecular elements did not occur. The
reducedtrabecularthicknesswasnotassociatedwithanincrease
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ment employs skeletonized images of trabecular profiles; that is,
the measurement is made from the middle of each trabecular
element rather than the edge. OPG-Fc administration increased
trabecular thickness and BMD, most likely owing to depletion of
osteoclasts and the refilling of existing resorption cavities by
osteoblasts during the 19 days of treatment with this agent
(Fig. 3A).
Cortical thickness at the femoral diaphysis was unaffected by
PTH, sRANKL, or OPG-Fc (not shown). A high coefficient of
variation prevented detection of effects of the treatments on
cancellous bone at the distal femur (not shown). Hence the
remainder of the study was focused on vertebral cancellous
bone.
The bone remodeling stimulated by sRANKL is
characterized by lower osteoblast number and activity
compared with PTH
Histomorphometric measurements done on nondecalcified
sections of vertebral cancellous bone showed that the increase
in osteoclast number caused by sRANKL was approximately
twofold greater than that caused by PTH (Fig. 3A). In contrast,
bone from animals receiving sRANKL or PTH exhibited an
equivalent increase in the number of osteoblasts. Importantly,
therefore, the ratio of osteoblasts to osteoclasts was greater in
PTH-treated mice than in sRANKL-treated mice (Fig. 3A). In other
words, for a given increase in osteoclasts, the corresponding rise
in osteoblast number was greater in mice infused with PTH than
in mice given sRANKL.
In both PTH- and sRANKL-treated animals, osteoblasts
exhibited typical plump cuboidal morphology adjacent to
osteoid, similar to that seen in vehicle-treated animals
(Fig. 3B). Accordingly, and consistent with the increase in
osteoblast number, osteoid surface was increased by both PTH
and sRANKL (Fig. 3B). Peritrabecular fibrosis was not observed in
any of the bone specimens. As we reported previously,
(30) the
prevalence of apoptotic osteoblasts was not affected by infusion
of PTH (Fig. 3C). Strikingly, however, sRANKL caused a reduction
in the prevalence of apoptotic osteoblasts.
Functional analysis indicated thatthe osteoblasts thatdevelop
in response to sRANKL had lower bone-formation capacity than
those that develop in response to PTH. Specifically, PTH
increased osteoid width, but sRANKL did not (Fig. 4A). Despite
the fact that PTH and sRANKL caused a similar increase in
osteoblast number, the increase in osteocalcin transcripts in
vertebral bone of sRANKL-treated mice was approximately one-
third that seen in PTH-treated mice. Moreover, PTH caused a
much greater increase in serum osteocalcin than sRANKL.
PTH increased bone formation, as indicated by alizarin red
labeling(givenonday3oftheexperiment),whereassRANKLhad
noeffect(Fig.4A).Tetracyclinewasgiven2dayspriortoinitiation
of infusion to permit determination of the effects of PTH and
Table 1. Changes in Body Weight and Total Serum Calcium
Treatment Body weight, % change Ca, mg/dL
Vehicle 0.8 6.8 9.8 1.4
PTH(1–84) 2.8 11.0 13.0 1.3
 
sRANKL 3.1 6.6 9.6 2.2
OPG-Fc 3.8 3.6 9.9 2.0
OPG-FcþPTH(1–84) 3.2 3.8 10.6 2.9
Note: n¼9 to 12/group.
 p<.05 versus vehicle.
Fig. 1. Experimental design. (A) Female Swiss Webster mice were treated as indicated to distinguish osteoclast (Oc)–dependent and –independent
mechanisms for increasing osteoblast number during PTH-stimulated bone remodeling. (B) The decline in osteoclasts and osteoblasts in vertebral bone
(L5)followingasingleinjectionof10mg/gofOPG-Fconday0wasmonitoredusingquantitativePCR(qPCR)attheindicatedtimestodetermineexpression
of the osteoclast-specific gene cathepsin K and the osteoblast-specific gene osteocalcin, relative to GAPDH (n¼6 to 8/group).
2430 Journal of Bone and Mineral Research JILKA ET AL.sRANKL on bone formation within existing BMUs by measuring
the double-labeled perimeter. Neither agent affected mineral
apposition rate (not shown). However, PTH, but not sRANKL,
increased the double-labeled perimeter and the bone-formation
rate (Fig. 4A, B). The failure to observe an sRANKL-stimulated
increase in bone-formation rate in the face of increased
osteocalcin and osteoid perimeter in this study may be due
to the fact that alizarin red labeling reflects osteoblast activity at
3 days after beginning infusion of PTH or sRANKL, whereas the
other indices reflect osteoblast activity at the end of the
experiment (ie, after 5 days of infusion). These findings indicate
that bone remodeling stimulated by sRANKL is unbalanced in
favor of bone resorption owing to inefficient generation of
osteoblasts with enough functional capacity to completely refill
the resorption cavity.
OPG prevents the PTH-stimulated increase in osteoblasts
Vertebral bone sections from mice receiving OPG-Fc for 14 days
prior to infusion of vehicle for 5 days exhibited few, if any,
osteoclasts or osteoblasts (Fig. 3A). As expected, OPG admin-
istration prior to PTH infusion prevented the increase in
osteoclast number. More important, PTH failed to significantly
increase osteoblast number in mice pretreated with OPG-Fc,
albeit a few osteoblasts overlying osteoid were noted in two of
the six bone sections. The very low number of osteoblasts
precludedaccuratedeterminationoftheprevalenceofapoptotic
osteoblasts in mice receiving OPG-Fc.
(36) Osteocalcin mRNA
expression and circulating osteocalcin, as well as labeling with
alizarin red, were sharply reduced in OPG-Fc-pretreated mice.
Under these conditions, PTH was unable to increase these
measures of osteoblast number and function (Fig. 4A). No
double-labeled surface was detected in mice receiving OPG-Fc,
without or with subsequent PTH infusion (Fig. 4A). Taken
together, these findings demonstrate that the increase in
osteoblasts caused by continuous elevation of PTH cannot occur
in the absence of BMUs.
PTH, but not sRANKL, attenuates sclerostin expression
and activates Wnt signaling
In view of evidence that sclerostin suppression and stimulation
of Wnt signaling promote osteoblast differentiation,
(22,23) we
wondered whether the smaller pro-osteoblastogenic effect of
sRANKL, compared with PTH, was due to the lack of effect of
sRANKL on the level of sclerostin. Western blotting of tibial
Fig. 2. sRANKL, but not PTH, decreases vertebral cancellous bone mass. Vertebral bone (L4) was analyzed by mCT. (A) Representative mCT images. (B)
Measurements of cancellous bone volume per tissue volume (BV/TV), BMD, trabecular thickness (Tb.Th), trabecular separation (Tb.Sp), and trabecular
number (Tb.N). n¼8 to 10/group.
 p<.05 versus vehicle (Veh) control.
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sclerostin, but sRANKL did not (Fig. 5A). PTH also increased
expression of the canonical Wnt target genes
(37) naked cuticle 2
homologue (Nkd2), Wnt1 inducible signaling pathway protein 1
(Wisp1), and Twist1 (Fig. 5B), but sRANKL had no effect on these
transcripts. Interestingly, the degree of PTH-induced suppression
of sclerostin in OPG-Fc-pretreated mice was the same as that in
controls. However, this response was not associated with
increased Wnt signaling, as measured by the expression of
the Wnt target genes.
In vitro studies with osteoblastic UAMS-32P and UMR 106 cells
showedthatPTHincreasedb-catenin/Tcf-mediatedtranscription
by twofold, as reflected by the activity of a Tcf-Luciferase reporter
construct (Fig. 5C). sRANKL, on the other hand, had no effect.
PTH, but not sRANKL, increases marrow vascularity
Blood vessels were quantified in nondecalcified vertebral bone
sections by immunostaining with an anti-CD34 antibody to
identify endothelial cells of vessels containing red blood cells
(Fig. 6A). This assay excludes sinusoidal structures of the bone
marrow, which have an irregular shape and lack a continuous
layer of CD34
þ endothelial cells. We found that PTH increased
the number of vessels in the bone marrow of the secondary
Fig. 3. Reduced osteoblast number in response to sRANKL compared with PTH and blockade of PTH effects by OPG-Fc. (A) Histomorphometric
determination of osteoclast (Oc) and osteoblast (Ob) numbers was done in vertebral cancellous bone sections (L1–L3). Owing to the severe reduction in
osteoblastsandosteoclastsinboneofmicepretreatedwithOPG,theratioofObtoOcwasnotcalculated(NC)inthesespecimens.(B)Photomicrographsof
osteoblasts (arrows) in animals receiving vehicle, PTH, or sRANKL. Nondecalcified sections, original magnification  400. Osteoid perimeter (O.Pm) was
determined as in panel A.( C) Prevalence of osteoblast apoptosis as determined by ISEL. Osteoblast apoptosis was not calculated (NC) in mice pretreated
with OPGowingto the very low numberof osteoblasts available for inspection.The photomicrograph shows anapoptoticosteoblast(black arrow) among
agroupofviableosteoblasts(whitearrows)inabonesectionfromasRANKL-treatedmouse.n¼4to6/group.
 p<.05versusvehicle(Veh)control;
yp<.05
versus PTH.
2432 Journal of Bone and Mineral Research JILKA ET AL.spongiosa by approximately 40% (Fig. 6B). Interestingly, neither
sRANKL nor OGP-Fc affected vessel number. Moreover, PTH
failed to increase blood vessels significantly in mice pretreated
with OPG-Fc.
Discussion
The coupling of bone formation to bone resorption during
remodeling requires activation of specific pathways that
promote the development and survival of osteoblasts. Based
on the data presented in this article and previous findings by our
laboratory and others, we propose a model to explain how
sustained elevation of PTH increases cancellous bone remodel-
ing while maintaining a focal balance between resorption and
formation within each BMU (Fig. 7). A sustained rise in PTH
increases the local concentration of RANKL and thereby the
development of new osteoclasts. Growth factors, such as
TGF-b,
(11) liberated by osteoclasts from the bone matrix, or
cardiotrophin 1 and BMP-6, produced by osteoclasts,
(12,13)
promote the differentiation and recruitment of osteoblasts to
the resorption cavity. However, the number and quality of these
osteoblastsareinsufficientforcompleterefillingofthecavity.For
this to occur, PTH must activate additional, osteoclast-indepen-
dent, pathways. Among these, the canonical Wnt signaling
pathway appears to be critical.
(19) Indeed, PTH activates Wnt
signaling by at least three complementary mechanisms:
activation of low density lipoprotein receptor-related protein 6
Fig. 4. Reduced osteoblast activity in mice receiving sRANKL compared with PTH and blockade of PTH effects by OPG-Fc. (A) Histomorphometric
determination of osteoid width (O.Wi), alizarin red (AR)–labeled perimeter, double-labeled surface (dL.Pm), and bone-formation rate (BFR) using the same
sectionsasinFig.3.OsteocalcintranscriptsweremeasuredbyqPCRofRNApreparationsfromvertebralbone(L4).SerumosteocalcinwasmeasuredbyRIA.
Osteoid width was not measured (NM) in mice pretreated with OPG-Fc. n¼4 to 6/group.
 p<.05 versus vehicle (Veh) control;
yp<.05 versus PTH. (B)
Double labeling with tetracycline and alizarin red in vertebral bone sections from mice infused with vehicle, PTH, or sRANKL. Original magnification  400.
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(20)increasedsynthesisofWntligands,
(16)andsuppression
of sclerostin production by osteocytes.
(18,21,22)
Despite the suppression of sclerostin and stimulation of Wnt
signaling by continuous elevation of PTH in the experiment
described herein, bone mass did not change. This is most likely
due to the fact that PTH also stimulated osteoclast differentia-
tion. Hence PTH increased cancellous bone remodeling that
remained balanced during this 5-day experiment. The evidence
that OPG-Fc pretreatment completely blocks the pro-osteo-
blastogenic effect of sustained elevation of PTH demonstrates
that the RANKL-stimulated osteoclast-dependent mechanism is
required for the osteoclast-independent mechanism to become
operational. One explanation for this dependency is that the
osteoblast progenitors that develop in response to factors
released from the bone matrix or from osteoclasts serve as
targets for the stimulatory effects of PTH on Wnt signaling via
activation of LRP6.
(20) These progenitors, as well as mature
osteoblasts, may also produce additional pro-osteoblastogenic
growth factors in response to PTH. Thus both the osteoclast-
dependent and -independent mechanisms may operate in
concert to generate and activate enough osteoblasts for
complete refilling of the resorption cavity.
The finding that PTH-induced suppression of sclerostin in
OPG-Fc-pretreated mice did not lead to increased Wnt signaling
and bone formation seems to conflict with evidence that
administration of an antisclerostin antibody to ovariectomized
rats dramatically increases bone formation.
(23) It is also
incongruent with evidence that depletion of osteoclasts by
pretreatmentwiththeantiresorptiveagentalendronatedoesnot
prevent the anabolic effect of sclerostin.
(38) Although additional
studies are needed to resolve this discrepancy, it is possible that
complete neutralization of sclerostin by the antibody treatment
constitutes a much stronger stimulus to canonical Wnt signaling
than the partial depletion of sclerostin afforded by continuous
elevation of PTH.
Stimulation of angiogenesis is a second and critical compo-
nent of the pro-osteoblastogenic effect of continuous PTH
elevation (Fig. 7). Like the full osteoblastogenic response,
Fig. 5. PTH, but not sRANKL, attenuates sclerostin expression and activates Wnt signaling. (A) Sclerostin was extracted from tibias and quantified by
Western blotting. Each lane represents one animal. Blots of three of the six samples in each group are shown.
 p<.05 versus vehicle (Veh) control. (B)
Expression of Nkd2, Wisp1, and Twist1 by qPCR of RNA from lumbar vertebrae (L4) relative to GAPDH. n¼8 to 10/group;
 p<.05 versus vehicle (Veh)
control;
yp<.05versusPTH.(C) Luciferaseactivity(relativelightunits,RLUs)in UAMS-32P andUMR106cellstransfectedwithaTCF-Lucreporterconstruct.
Activity was measured 24hours after addition of vehicle (0.01% acetic acid), 50 nM PTH(1-34), or 100ng/mL of sRANKL. n¼3/group.
 p<.05 versus
vehicle.
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dent and -independent mechanisms. Moreover, the inability of
sRANKL to generate enough osteoblasts to refill the resorption
cavity is associated with the failure of the cytokine to stimulate
angiogenesis. This result adds support to the notion that
angiogenesis plays a critical role in osteoblastogenesis. Capil-
laries may be essential for balanced bone remodeling because of
their ability to deliver mesenchymal stem cell progenitors of
osteoblasts to the site of bone formation.
(26) These progenitors,
also known as pericytes, reside on the outside surfaces of blood
vessels. Pericytes also produce an extracellular matrix and
growth factors such as TGF-b that support the development and
function of endothelial cells. The dual function of pericytes thus
may contribute to the close linkage of angiogenesis and bone
formation.
Increased capillaries were noted 25 years ago in bone biopsies
from patients with hyperparathyroidism.
(39) Moreover, such
patients exhibit an increase in the number of circulating
endothelial cell progenitors, as defined by their expression of
CD45, CD34, and CD31 surface antigens.
(40) Interestingly,
injections of PTH-related protein (PTHrP) four times a day for
5 days increased angiogenesis in the diploe of 7-week-old
mice.
(41) Rats given daily injections of PTH also exhibited
increased blood vessels near sites of bone formation but no
increase in vessel density in the bone as a whole, as revealed by
high-resolution mCT imaging.
(42) Moreover, intermittent admin-
istration of PTH to mice with ischemic heart disease stimulated
the migration of endothelial progenitors to and increased
neovascularization of the damaged heart tissue.
(43) Be that as it
may, further studies will be needed to elucidate differences and
similaritiesbetweentheeffectsofcontinuousversusintermittent
elevation of PTH on blood vessel development in bone and the
relationship of new vessels to sites of bone formation.
At this stage, the mechanism by which PTH increases the
number of marrow blood vessels is unclear. Besides stimulation
of VEGF and angiopoetin 1 synthesis,
(27,28) PTH-activated
canonical Wnt signaling may be involved because Wnts, TGF-
b, and VEGF may act in concert to promote the development of
blood vessels.
(44,45) PTH-stimulated osteoblastogenesis also
could contribute to new blood vessel formation in view of
evidence that low oxygen tension, which occurs in osteocytes
owing to their distance from blood vessels, stimulates the
expression of VEGF by osteoblasts/osteocytes and thereby
promotes angiogenesis.
(46–48)
PTH may also increase angiogenesis indirectly via stimulation
of osteoclastogenesis because osteoclasts have been shown to
promote blood vessel formation by producing matrix metallo-
proteinase9,whichreleasesgrowthfactorsfromtheextracellular
matrix.
(41) As we observed, OPG prevented the proangiogenic
Fig. 6. PTH, but not sRANKL, increases marrow vascularity. (A) Photomicrograph of blood vessels in the marrow of secondary spongiosa of lumbar
vertebrae. Vessels were recognized by CD34
þ endothelial cells (arrows) of vessels containing red blood cells. Original magnification  200.
(B) Histomorphometric determination of blood vessels in the marrow space adjacent to the secondary spongiosa. n¼4 to 6/group;
 p<.05 versus
vehicle (Veh) control;
yp<.05 versus PTH.
Fig. 7. PTH-stimulated osteoclast-dependent and -independent
mechanisms involved in the control of osteoblast number during bone
remodeling. See text for details. HSC¼hematopoietic stem cell progeni-
tors of osteoclasts; Oc¼osteoclasts; MSC¼mesenchymal stem cell
progenitors of osteoblasts; Ob¼osteoblasts; ECP¼endothelial cell pro-
genitors; GF¼growth factors.
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(41) However,
in contrast to our findings, sRANKL stimulated angiogenesis
when injected subcutaneously over calvaria of growing 7-week-
old mice four times per day.
(41) This seeming discrepancy most
likelyreflectsmethodologicdifferencesbetweenthetwostudies,
including local versus systemic administration of sRANKL,
calvaria versus the axial skeleton, and/or the age of the animals.
Despite the failure of sRANKL to generate an adequate
number of active osteoblasts to refill the resorption cavity, those
that did develop exhibited a low prevalence of apoptosis. Hence
the initial osteoblastogenic response mediated by osteoclasts
was magnified by prolongation of osteoblast lifespan. In situ
hybridization studies have shown that RANK is not expressed by
osteoblasts in vivo.
(49) Thus the antiapoptotic actions of sRANKL
on osteoblasts probably are mediated indirectly by release of
factors from the bone matrix or from osteoclasts. In support of
this notion, TGF-b, an established inhibitor of osteoblast
apoptosis,
(50) is released from the bone matrix in vivo and in
vitro.
(11) As shown in this and an earlier study of ours,
(30)
continuously elevated PTH has no effect on osteoblast apoptosis
invivo.Thusindirectpro-survival effects ofRANKL onosteoblasts
in the hyperparathyroid state may be counterbalanced by direct
or indirect proapoptotic actions of the hormone. In support of
this notion, we have demonstrated previously that more than
6hours of exposure of osteoblastic cells to PTH suppresses the
synthesis of Runx2,
(30) which is required for the pro-survival
effects of the hormone. In addition, Chen and colleagues have
reported that long-term culture of osteoblastic cells with PTH
stimulates osteoblast apoptosis.
(51)
The antiapoptotic effect of sRANKL on osteoblasts raises the
possibility that OPG-Fc stimulates apoptosis. We were unable to
measure the prevalence of apoptotic osteoblasts in mice
receiving OPG-Fc because of the paucity of osteoblasts.
However, the relatively slow decline in osteoblasts following
administration of OPG-Fc, together with the demonstration that
OPG-Fc increased BMD, indicates that viable osteoblasts refilled
the resorption cavities in OPG-Fc-treated mice. In contrast, OPG-
Fc caused a rapid decline in osteoclast number, as would be
expected by the loss of the pro-differentiating and pro-survival
effectsofRANKLonosteoclasts.Administrationofalendronateto
mice has the same effect as OPG-Fc on vertebral osteoclast and
osteoblast number, as well as cancellous bone volume.
(52) Thus,
at this stage, the evidence does not support the hypothesis that
OPG-Fc stimulates osteoblast apoptosis.
In summary, we have shown that PTH-stimulated bone
remodeling maintains a focal balance between bone resorption
and bone formation in cancellous bone by increasing both
osteoclasts and osteoblasts. We propose that the latter occurs in
part via a RANKL-stimulated osteoclast-mediated component.
However, complete refilling of the resorption cavity requires
additional actions of PTH that unleash canonical Wnt signaling
and stimulate angiogenesis. Future advances in our under-
standing of the mechanisms responsible for balanced versus
unbalanced remodeling will require elucidation of the mechan-
ism(s) by which Wnt signaling and other factors induced by PTH
promote the proliferation, differentiation, and recruitment of
osteoblasts to the BMU, as well as investigation of the role of
angiogenesis in the regulation of bone remodeling.
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